ES2399147T3 - Tratamiento, prevención y reversión de una enfermedad hepática alcohólica - Google Patents

Tratamiento, prevención y reversión de una enfermedad hepática alcohólica Download PDF

Info

Publication number
ES2399147T3
ES2399147T3 ES07837941T ES07837941T ES2399147T3 ES 2399147 T3 ES2399147 T3 ES 2399147T3 ES 07837941 T ES07837941 T ES 07837941T ES 07837941 T ES07837941 T ES 07837941T ES 2399147 T3 ES2399147 T3 ES 2399147T3
Authority
ES
Spain
Prior art keywords
ppar
agonist
treatment
liver
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07837941T
Other languages
English (en)
Spanish (es)
Inventor
Suzanne Marie De La Monte
Jack Raymond Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ES2399147T3 publication Critical patent/ES2399147T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES07837941T 2006-09-08 2007-09-10 Tratamiento, prevención y reversión de una enfermedad hepática alcohólica Active ES2399147T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84298306P 2006-09-08 2006-09-08
US842983P 2006-09-08
PCT/US2007/019610 WO2008030595A2 (en) 2006-09-08 2007-09-10 Treatment, prevention, and reversal of alcohol-induced liver disease

Publications (1)

Publication Number Publication Date
ES2399147T3 true ES2399147T3 (es) 2013-03-26

Family

ID=39157885

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07837941T Active ES2399147T3 (es) 2006-09-08 2007-09-10 Tratamiento, prevención y reversión de una enfermedad hepática alcohólica

Country Status (8)

Country Link
US (1) US9717719B2 (https=)
EP (1) EP2061484B1 (https=)
JP (1) JP5864077B2 (https=)
KR (1) KR101922515B1 (https=)
AU (1) AU2007292874B2 (https=)
CA (1) CA2663115C (https=)
ES (1) ES2399147T3 (https=)
WO (1) WO2008030595A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
CA3091774A1 (en) * 2018-02-20 2019-08-29 EMULATE, Inc. Human microphysiological cell system for liver disease conversion with prov 1-18585 and prov 2-19154
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
CN113244225B (zh) * 2021-06-16 2022-06-28 昆明医科大学第一附属医院 土槿皮乙酸在制备抗血小板药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058785B (en) * 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6713514B1 (en) 1999-04-19 2004-03-30 Lexicon Pharmaceuticals, Inc. PPAR-γ agonists as agents for the treatment of type II diabetes
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6462046B2 (en) 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
EP1278749B1 (en) * 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2002002138A1 (en) 2000-07-03 2002-01-10 Probendo Pty Ltd Treating endotoxemia and related disorders with probiotics
CA2417005A1 (en) 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2003016265A1 (en) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
AU2003250441A1 (en) * 2002-08-20 2004-03-11 Koninklijke Philips Electronics N.V. Mobile network authentication for protecting stored content
CA2499380A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
WO2005009437A1 (en) * 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
EP1682507A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1742923B1 (en) 2004-04-28 2009-05-27 F.Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators

Also Published As

Publication number Publication date
EP2061484B1 (en) 2012-11-07
AU2007292874B2 (en) 2013-11-21
KR20090086941A (ko) 2009-08-14
KR101922515B1 (ko) 2019-02-20
EP2061484A2 (en) 2009-05-27
US9717719B2 (en) 2017-08-01
WO2008030595A2 (en) 2008-03-13
CA2663115A1 (en) 2008-03-13
EP2061484A4 (en) 2010-01-13
US20100021386A1 (en) 2010-01-28
JP5864077B2 (ja) 2016-02-17
WO2008030595A3 (en) 2008-06-26
AU2007292874A1 (en) 2008-03-13
JP2010502718A (ja) 2010-01-28
CA2663115C (en) 2015-04-28

Similar Documents

Publication Publication Date Title
Haga et al. The survival pathways phosphatidylinositol‐3 kinase (PI3‐K)/phosphoinositide‐dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation
Moles et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis
Rmilah et al. Hormonal contribution to liver regeneration
Hu et al. Src promotes anti-inflammatory (M2) macrophage generation via the IL-4/STAT6 pathway
ES2399147T3 (es) Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
Zhong et al. Curcumin improves insulin sensitivity in high-fat diet-fed mice through gut microbiota
Lv et al. Spexin/NPQ induces FBJ osteosarcoma oncogene (Fos) and produces antinociceptive effect against inflammatory pain in the mouse model
Kim et al. GPx7 ameliorates non-alcoholic steatohepatitis by regulating oxidative stress
Ciuclan et al. TGF-β enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I
Song et al. PI3Ka-Akt1-mediated Prdm4 induction in adipose tissue increases energy expenditure, inhibits weight gain, and improves insulin resistance in diet-induced obese mice
Sud et al. Activation of the dsRNA-activated protein kinase PKR in mitochondrial dysfunction and inflammatory stress in metabolic syndrome
Yang et al. Hepatic E4BP4 induction promotes lipid accumulation by suppressing AMPK signaling in response to chemical or diet-induced ER stress
Ai et al. A20 attenuates FFAs-induced lipid accumulation in nonalcoholic steatohepatitis
Liu et al. Postprandial exercise regulates tissue-specific triglyceride uptake through angiopoietin-like proteins
US9693994B2 (en) Class IIa HDAC inhibitors for the treatment of infection
Martucci et al. A Novel Role for the Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation
US20100160339A1 (en) Treating pancreatitis
US20240148764A1 (en) Inhibitors of sglt-1 and uses thereof
Ramadan Mohamed et al. JNKs protect from cholestatic liver disease progression by modulating Apelin signalling
Bakiri Liver cancer development driven by the AP-1/c-Jun~ Fra-2 dimer through c-Myc (Author copy)
Alegre et al. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz. Biomedicines 2022, 10, 109
Zhou et al. TLR5 Signaling Ameliorates Liver Fibrosis by Inducing Interferon β-Interleukin-1 Receptor Antagonist in Mice
An The Role of Sulfotransferase 2B1b in Acetaminophen-induced Liver Injury
Castellanos Pancreatic Cancer Chemoprevention by Metformin in a High Fat Diet
WO2017068227A1 (es) Métodos para utilizar reguladores de aumento de la expresión o activación de p53 y/o reguladores de disminución o inhibidores de la expresión de p63-alfa para el tratamiento de nafld (enfermedad de hígado graso no-alcohólico) y/o nash (esteatohepatitis no- alcohólica)